NYSE:PTHN Patheon N.V. Ordinary shares, p (PTHN) Stock Price, News & Analysis → Silver Expected for Extreme Price Action (From Colonial Metals) (Ad) Free PTHN Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$34.98▼$34.9850-Day Range N/A52-Week Range$23.72▼$35.13VolumeN/AAverage VolumeN/AMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Patheon N.V. Ordinary shares, p alerts: Email Address Ad InvestorPlaceJeff Bezos & 48 Members of Congress Are Buying ONE Sector…Why are Warren Buffett, Jeff Bezos, Michael Bloomberg, “The Walmart Family”, Bill Gates, and 48 members of Congress shifting their stocks in a frenzy? And why are they all piling into ONE unique corner of the market…Click here for the details About Patheon N.V. Ordinary shares, p Stock (NYSE:PTHN)Patheon N.V. is a provider of outsourced pharmaceutical development and manufacturing services. The Company's segments include Drug Product Services (DPS), Pharmaceutical Development Services (PDS) and Drug Substance Services (DSS). The DPS segment is engaged in manufacturing and packaging for approved prescription, over-the-counter (OTC) and nutritional products. The PDS segment provides a range of formulation, production and technical services from the early stages of a product's development to regulatory approval, as well as for new formulations of approved products for lifecycle extension. The DSS segment provides small molecule active pharmaceutical ingredient (API) and outsourced manufacturing solutions for large molecule biological API from early development through commercial scale production. It provides an integrated range of API and finished drug product services to its customers, from formulation development to clinical and commercial-scale manufacturing.Read More Ad InvestorPlaceJeff Bezos & 48 Members of Congress Are Buying ONE Sector…Why are Warren Buffett, Jeff Bezos, Michael Bloomberg, “The Walmart Family”, Bill Gates, and 48 members of Congress shifting their stocks in a frenzy? And why are they all piling into ONE unique corner of the market…Click here for the details PTHN Stock News HeadlinesMay 9, 2024 | morningstar.comCTP NV Ordinary SharesMay 9, 2024 | morningstar.comLilium NV Ordinary Shares - Class A LILMApril 15, 2024 | money.usnews.comCloudflare Inc - Ordinary Shares - Class AMarch 19, 2024 | money.usnews.comChain Bridge I - Ordinary Shares - Class AFebruary 28, 2024 | nasdaq.comYandex N.V. Class A Ordinary Shares (YNDX)February 27, 2024 | money.usnews.comAon plc. - Ordinary Shares - Class AFebruary 23, 2024 | morningstar.comThe Kingfish Co NV Ordinary Shares KINGFebruary 21, 2024 | money.usnews.comKinder Morgan Inc - Ordinary Shares - Class PFebruary 14, 2024 | morningstar.comJDE Peets NV Ordinary SharesDecember 12, 2023 | nasdaq.comEaton Corporation, PLC Ordinary Shares (ETN)December 2, 2023 | morningstar.comIveco Group NV Ordinary SharesNovember 14, 2023 | finance.yahoo.comPatheon N.V. Ordinary shares, p (PTHN)November 13, 2023 | lse.co.ukEase2pay Nv Share Price (EAS2P.AM)November 11, 2023 | lse.co.ukNew Amsterdam Invest N.v. Ordinary Shares Share ChatOctober 29, 2023 | morningstar.comInPoint Commercial Real Estate Income Inc Ordinary Shares - Class PSeptember 28, 2023 | morningstar.comWallbox NV Class A Ordinary ShareSeptember 1, 2023 | money.usnews.comCrowdstrike Holdings Inc - Ordinary Shares - Class AAugust 16, 2023 | money.usnews.comXPEL Inc - Ordinary Shares - Reg SAugust 15, 2023 | morningstar.comCureVac NV Ordinary SharesAugust 4, 2023 | health.usnews.comKeesha P. KaplanJuly 31, 2023 | nasdaq.comLifezone Metals Limited Ordinary Shares (LZM)July 21, 2023 | uk.investing.comFT Ordinary Share (FTII)July 19, 2023 | nasdaq.comNewAmsterdam Pharma Company N.V. Ordinary Shares (NAMS)June 28, 2023 | money.usnews.comComcast Corp - Ordinary Shares - Class AJune 19, 2023 | finance.yahoo.comImproved Earnings Required Before RoodMicrotec N.V. (AMS:ROOD) Shares Find Their FeetSee More Headlines Receive PTHN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Patheon N.V. Ordinary shares, p and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings6/08/2017Today6/16/2024Fiscal Year End10/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNYSE:PTHN Previous SymbolNASDAQ:PTHN CUSIPN/A CIK1643848 Webwww.patheon.com Phone31-20-622-3243FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesPaul S. LevyChairman of the BoardJames C. MullenChief Executive Officer, DirectorStuart R. GrantChief Financial Officer, Executive Vice PresidentGilles A. CottierPresident - Global Pharmaceutical Development ServicesFranco NegronPresident - Drug Product ServicesLukas UtigerPresident - Drug SubstanceMichael J. LehmannExecutive Vice President - Global Sales and MarketingMichael E. Lytton J.D.Executive Vice President - Corporate Development and StrategyRebecca Holland NewChief Human Resources Officer and Executive Vice President - Communications and Project Management OfficeHarry R. Gill IIISenior Vice President - Quality and Continuous ImprovementMore ExecutivesKey CompetitorsLAVA TherapeuticsNASDAQ:LVTXMainz BiomedNASDAQ:MYNZNLS PharmaceuticsNASDAQ:NLSPOncoSec MedicalNASDAQ:ONCSQPharvarisNASDAQ:PHVSView All Competitors PTHN Stock Analysis - Frequently Asked Questions How were Patheon N.V. Ordinary shares, p's earnings last quarter? Patheon N.V. Ordinary shares, p (NYSE:PTHN) released its quarterly earnings data on Thursday, June, 8th. The company reported $0.20 earnings per share for the quarter, beating the consensus estimate of $0.19 by $0.01. The firm earned $483.40 million during the quarter, compared to analysts' expectations of $466.08 million. The firm's quarterly revenue was up 3.2% on a year-over-year basis. What other stocks do shareholders of Patheon N.V. Ordinary shares, p own? Based on aggregate information from My MarketBeat watchlists, some companies that other Patheon N.V. Ordinary shares, p investors own include SVB Financial Group (SIVB), Skyworks Solutions (SWKS), Wells Fargo & Company (WFC), Alexion Pharmaceuticals (ALXN), NXP Semiconductors (NXPI), Bank of the Ozarks (OZRK), Clearside Biomedical (CLSD), Coherus BioSciences (CHRS), Gemphire Therapeutics (GEMP) and JetBlue Airways (JBLU). When did Patheon N.V. Ordinary shares, p IPO? Patheon N.V. Ordinary shares, p (PTHN) raised $625 million in an initial public offering (IPO) on Thursday, July 21st 2016. The company issued 30,500,000 shares at $19.00-$22.00 per share. J.P. Morgan, Morgan Stanley, Jefferies, UBS Investment Bank, Credit Suisse, Evercore ISI and Wells Fargo Securities acted as the underwriters for the IPO and Baird, Piper Jaffray, Raymond James, William Blair, KeyBanc Capital Markets and Leerink Partners were co-managers. This page (NYSE:PTHN) was last updated on 6/16/2024 by MarketBeat.com Staff From Our PartnersTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredHurry! Buy this stock before the Robinhood traders do!Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredThe Only Energy Play You Should Be Looking AtOpen AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has alr...Wealthpin Pro | SponsoredFinancial Stranglehold on the U.S.What This Group Has Planned for the 2024 Election Will Shock You Controversial new exposé reveals what’s re...Porter & Company | SponsoredAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredThe #1 Crypto That You Don’t Own… YetThere’s all kinds of “signals” to follow when investing in cryptos. But there’s one signal you should pay a...Crypto 101 Media | SponsoredMust-See: Elon’s New Invention is Absolutely InsaneCould Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Patheon N.V. Ordinary shares, p Please log in to your account or sign up in order to add this asset to your watchlist. Share Patheon N.V. Ordinary shares, p With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.